



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2017





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2017 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

June 2017

N = 7239



Health Authority	Male	Female	All
FRASER	1376	398	1774
INTERIOR	379	96	475
NORTHERN	132	78	210
VANCOUVER COASTAL	3416	450	3866
VANCOUVER ISLAND	717	163	880
	<b>6020</b>	<b>1185</b>	<b>7205</b>
		<b>Unknown/not stated:</b>	<b>34</b>
		<b>Total:</b>	<b>7239</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2012 - June 2017)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2012 - June 2017)






### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2012 - June 2017)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (June 2012 - June 2017)






1.6 Percent Distribution of Active Participants by CD4 Count (June 2012 - June 2017)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (June 2012 - June 2017)






### 1.8 Active and Inactive Participants (June 2012 - June 2017)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2012 - June 2017)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (June 2012 - June 2017)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(June 2012 - June 2017)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (June 2012 - June 2017)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(June 2012 - June 2017)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2012 - June 2017)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(June 2012 - June 2017)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (June 2012 - June 2017)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(June 2012 - June 2017)






1.18 Baseline CD4 for Antiretroviral First Starts  
(June 2012 - June 2017)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (June 2012 - June 2017)






### 1.20 Cumulative Resistance Testing Results by Resistance Category (June 2012 - June 2017)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (June 2012 - June 2017)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2017  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	25	5	0	5	5	630	5	<40	3
1988	25	7	0	7	7	590	7	<40	3
1989	24	57	2	59	50	500	57	<40	3
1990	23	62	1	63	57	540	63	<40	3
1991	23	38	3	41	33	570	40	<40	3
1992	23	70	7	77	61	530	76	<40	3
1993	22	144	16	160	144	540	156	<40	3
1994	21	90	15	105	94	560	103	<40	3
1995	20	124	22	146	122	555	140	<40	3
1996	18	366	60	426	364	580	407	<40	3
1997	17	291	37	328	296	610	312	<40	3
1998	16	208	45	253	217	560	236	<40	3
1999	16	171	43	214	190	540	207	<40	3
2000	16	134	37	171	153	570	166	<40	3
2001	16	125	32	157	133	590	148	<40	3
2002	14	137	30	167	146	560	161	<40	3
2003	14	168	30	198	168	590	189	<40	3
2004	13	175	41	216	180	590	203	<40	3
2005	12	193	47	240	207	600	226	<40	3
2006	11	201	45	246	207	580	235	<40	3
2007	10	276	54	330	274	607	304	<40	3
2008	9	310	72	382	324	620	363	<40	3
2009	8	339	76	415	349	640	390	<40	3
2010	7	303	70	373	310	615	352	<40	3
2011	6	349	74	423	371	670	399	<40	3
2012	5	293	60	353	311	660	340	<40	3
2013	4	281	70	351	295	620	341	<40	3
2014	3	310	57	367	300	690	339	<40	3
2015	2	323	56	379	331	650	361	<40	3
2016	1	321	68	389	338	590	376	<40	3
2017	0	161	19	180	176	530	178	<40	3
<b>Total:</b>		<b>6032</b>	<b>1189</b>	<b>7221</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	6970	737	2262	<40	2022	590
FEB-2016	6989	735	2064	<40	1865	590
MAR-2016	6995	737	2155	<40	1958	590
APR-2016	7014	734	2053	<40	1864	580
MAY-2016	7043	747	2071	<40	1885	590
JUN-2016	7062	739	2179	<40	1991	610
JUL-2016	7052	749	1949	<40	1760	600
AUG-2016	7069	750	2068	<40	1877	590
SEP-2016	7108	752	2214	<40	1999	600
OCT-2016	7138	747	2153	<40	1935	600
NOV-2016	7169	742	2110	<40	1901	580
DEC-2016	7192	752	1872	<40	1704	620
JAN-2017	7182	749	2324	<40	2065	590
FEB-2017	7133	755	1913	<40	1729	590
MAR-2017	7185	746	2201	<40	1982	600
APR-2017	7180	748	1965	<40	1730	590
MAY-2017	7227	749	2280	<40	1965	590
JUN-2017	7239	753	2117	<40	1830	600

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	1512	2278	116	<40	104	465
FEB-2016	1504	2315	83	353	74	380
MAR-2016	1511	2296	87	130	83	440
APR-2016	1515	2286	87	<50	74	360
MAY-2016	1499	2374	79	<40	69	350
JUN-2016	1510	2358	72	76	56	505
JUL-2016	1534	2309	81	<50	75	460
AUG-2016	1558	2223	94	158	78	360
SEP-2016	1545	2276	96	240	80	360
OCT-2016	1519	2449	74	<40	70	415
NOV-2016	1516	2490	73	1007	58	380
DEC-2016	1517	2511	52	122	44	480
JAN-2017	1533	2499	88	140	78	417
FEB-2017	1590	2257	80	1328	67	400
MAR-2017	1545	2445	101	635	88	370
APR-2017	1562	2408	95	517	84	420
MAY-2017	1533	2542	82	148	67	420
JUN-2017	1534	2554	79	153	69	480

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





**2.4 BC-CfE Enrollment**

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2016	6940	1512	9	16	152	168	-12	12409
FEB-2016	6960	1504	5	18	178	163	20	12437
MAR-2016	6968	1511	9	24	170	173	8	12471
APR-2016	6987	1515	6	20	166	157	19	12505
MAY-2016	7018	1499	7	23	159	142	31	12536
JUN-2016	7032	1510	12	34	163	167	14	12579
JUL-2016	7015	1534	11	25	136	157	-17	12611
AUG-2016	7031	1558	10	40	165	172	16	12671
SEP-2016	7073	1545	5	27	179	151	42	12714
OCT-2016	7101	1519	11	22	161	138	28	12745
NOV-2016	7127	1516	20	27	181	160	26	12791
DEC-2016	7149	1517	11	25	154	142	22	12831
JAN-2017	7144	1533	21	22	140	144	-5	12863
FEB-2017	7104	1590	10	24	136	186	-40	12897
MAR-2017	7152	1545	17	19	187	139	48	12923
APR-2017	7147	1562	12	20	144	154	-5	12955
MAY-2017	7205	1533	7	22	173	128	58	12989
JUN-2017	7221	1534	6	23	148	144	16	13018

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2016	58	6405	446	61	<b>6970</b>	0.83%	91.89%	6.40%	0.88%	<b>100.00%</b>
FEB-2016	59	6436	435	59	<b>6989</b>	0.84%	92.09%	6.22%	0.84%	<b>100.00%</b>
MAR-2016	54	6442	438	61	<b>6995</b>	0.77%	92.09%	6.26%	0.87%	<b>100.00%</b>
APR-2016	54	6464	439	57	<b>7014</b>	0.77%	92.16%	6.26%	0.81%	<b>100.00%</b>
MAY-2016	57	6495	437	54	<b>7043</b>	0.81%	92.22%	6.20%	0.77%	<b>100.00%</b>
JUN-2016	60	6499	447	56	<b>7062</b>	0.85%	92.03%	6.33%	0.79%	<b>100.00%</b>
JUL-2016	57	6496	442	57	<b>7052</b>	0.81%	92.12%	6.27%	0.81%	<b>100.00%</b>
AUG-2016	57	6509	447	56	<b>7069</b>	0.81%	92.08%	6.32%	0.79%	<b>100.00%</b>
SEP-2016	58	6546	447	57	<b>7108</b>	0.82%	92.09%	6.29%	0.80%	<b>100.00%</b>
OCT-2016	58	6578	445	57	<b>7138</b>	0.81%	92.15%	6.23%	0.80%	<b>100.00%</b>
NOV-2016	61	6603	446	59	<b>7169</b>	0.85%	92.10%	6.22%	0.82%	<b>100.00%</b>
DEC-2016	62	6635	437	58	<b>7192</b>	0.86%	92.26%	6.08%	0.81%	<b>100.00%</b>
JAN-2017	61	6615	443	63	<b>7182</b>	0.85%	92.11%	6.17%	0.88%	<b>100.00%</b>
FEB-2017	60	6578	440	55	<b>7133</b>	0.84%	92.22%	6.17%	0.77%	<b>100.00%</b>
MAR-2017	60	6628	438	59	<b>7185</b>	0.84%	92.25%	6.10%	0.82%	<b>100.00%</b>
APR-2017	59	6633	429	59	<b>7180</b>	0.82%	92.38%	5.97%	0.82%	<b>100.00%</b>
MAY-2017	62	6668	438	59	<b>7227</b>	0.86%	92.27%	6.06%	0.82%	<b>100.00%</b>
JUN-2017	57	6687	437	58	<b>7239</b>	0.79%	92.37%	6.04%	0.80%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	4 19%	2818 42%	4 19%	2485 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	17 81%	4165 62%
FEB-2016	10 36%	2851 42%	9 32%	2519 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	18 64%	4135 61%
MAR-2016	9 26%	2877 43%	7 21%	2542 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	26 76%	4112 61%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	5 0%	22 65%	4103 60%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	0 0%	6 0%	23 74%	4120 61%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	1 2%	9 0%	31 72%	4117 60%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	0 0%	9 0%	23 72%	4113 60%
AUG-2016	11 19%	2936 43%	11 19%	2626 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	6 10%	22 0%	42 71%	4097 60%
SEP-2016	14 33%	2969 43%	12 28%	2659 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	3 7%	25 0%	27 63%	4102 60%
OCT-2016	11 35%	2997 43%	11 35%	2689 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	0 0%	26 0%	20 65%	4098 59%
NOV-2016	17 37%	3023 44%	17 37%	2722 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	0 0%	35 1%	29 63%	4088 59%
DEC-2016	7 18%	3058 44%	7 18%	2753 40%	0 0%	77 1%	0 0%	6 0%	0 0%	6 0%	0 0%	35 1%	33 83%	4077 59%
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3073 44%	10 29%	2782 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3104 45%	7 27%	2823 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3115 45%	12 38%	2835 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3963 57%
MAY-2017	9 26%	3157 45%	9 26%	2879 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	120 2%	24 71%	3935 56%
JUN-2017	5 17%	3165 45%	5 17%	2898 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	142 2%	22 76%	3894 55%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2016	17	81%	3848	57%
FEB-2016	18	64%	3828	57%
MAR-2016	25	74%	3809	56%
APR-2016	22	65%	3812	56%
MAY-2016	23	74%	3834	56%
JUN-2016	32	74%	3829	56%
JUL-2016	23	72%	3830	56%
AUG-2016	48	81%	3831	56%
SEP-2016	29	67%	3847	56%
OCT-2016	20	65%	3848	56%
NOV-2016	29	63%	3852	56%
DEC-2016	33	83%	3843	55%
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3792	55%
MAY-2017	25	74%	3800	54%
JUN-2017	24	83%	3794	54%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1128 34%	1 9%	326 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1155 35%	1 8%	317 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1197 37%	0 0%	293 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1220 38%	0 0%	282 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1235 38%	0 0%	283 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1689 53%	11 79%	1242 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1663 52%	26 90%	1254 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1269 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1615 51%	9 82%	1263 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	3 16%	1588 51%	15 79%	1282 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
DEC-2016	0 0%	9 0%	3 17%	1588 50%	15 83%	1305 41%	0 0%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1517 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1512 49%	11 92%	1328 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1483 49%	5 71%	1319 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1351 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1449 48%	9 82%	1359 45%	0 0%	220 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%
DEC-2016	0	0%	1	0%
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	996 41%	0 0%	307 13%	1 25%	854 35%	1 25%	257 11%
APR-2016	3 33%	990 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	969 41%	1 25%	299 13%	2 50%	836 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	295 13%	0 0%	830 35%	2 29%	262 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	819 35%	2 50%	265 11%
OCT-2016	1 20%	944 41%	2 40%	300 13%	1 20%	814 35%	1 20%	269 12%
NOV-2016	7 88%	936 41%	1 13%	294 13%	0 0%	812 35%	0 0%	269 12%
DEC-2016	7 70%	927 40%	0 0%	290 13%	0 0%	805 35%	3 30%	273 12%
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	898 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	889 40%	0 0%	273 12%	1 11%	787 35%	4 44%	271 12%
MAY-2017	3 75%	878 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	6 55%	1020 44%	4 36%	458 20%	0 0%	66 3%	1 9%	821 35%	0 0%	1 0%
FEB-2016	7 64%	1062 45%	4 36%	468 20%	0 0%	60 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1115 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1153 47%	4 22%	491 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1182 47%	4 24%	493 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	517 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1305 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1412 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1452 52%	5 20%	580 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%
DEC-2016	9 75%	1479 52%	2 17%	587 21%	0 0%	53 2%	1 8%	762 27%	0 0%	1 0%
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1619 55%	2 13%	602 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1656 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	603 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	11 73%	1756 57%	3 20%	595 19%	0 0%	49 2%	1 7%	712 23%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2016	2285	32.78	1944	27.89	1609	23.08	158	2.27	61	0.88	913	13.10
FEB-2016	2279	32.61	1925	27.54	1668	23.87	153	2.19	59	0.84	905	12.95
MAR-2016	2266	32.39	1903	27.21	1706	24.39	154	2.20	61	0.87	905	12.94
APR-2016	2244	31.99	1894	27.00	1757	25.05	154	2.20	57	0.81	908	12.95
MAY-2016	2256	32.03	1887	26.79	1781	25.29	157	2.23	54	0.77	908	12.89
JUN-2016	2255	31.93	1877	26.58	1811	25.64	152	2.15	56	0.79	911	12.90
JUL-2016	2225	31.55	1865	26.45	1847	26.19	150	2.13	57	0.81	908	12.88
AUG-2016	2210	31.26	1839	26.01	1913	27.06	142	2.01	56	0.79	909	12.86
SEP-2016	2191	30.82	1831	25.76	1977	27.81	144	2.03	57	0.80	908	12.77
OCT-2016	2169	30.39	1829	25.62	2033	28.48	146	2.05	57	0.80	904	12.66
NOV-2016	2174	30.33	1817	25.35	2074	28.93	143	1.99	59	0.82	902	12.58
DEC-2016	2181	30.33	1808	25.14	2102	29.23	143	1.99	58	0.81	900	12.51
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2124	29.78	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2132	29.67	1755	24.43	2222	30.93	134	1.86	59	0.82	883	12.29
APR-2017	2108	29.36	1745	24.30	2260	31.48	133	1.85	59	0.82	875	12.19
MAY-2017	2109	29.18	1738	24.05	2309	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2112	29.18	1719	23.75	2348	32.44	132	1.82	58	0.80	870	12.02

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	23	2	1	3	4	13	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	27	3	4	5	7	8	390
DEC-2016	25	4	1	5	3	11	410
JAN-2017	22	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	4	8	8	395
JUN-2017	23	6	2	5	3	7	230

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2016	11049	3054
FEB-2016	11142	3135
MAR-2016	11202	3183
APR-2016	11249	3217
MAY-2016	11309	3266
JUN-2016	11365	3297
JUL-2016	11408	3332
AUG-2016	11453	3338
SEP-2016	11480	3342
OCT-2016	11511	3366
NOV-2016	11553	3387
DEC-2016	11583	3398
JAN-2017	11604	3419
FEB-2017	11631	3428
MAR-2017	11682	3477
APR-2017	11709	3493
MAY-2017	11751	3519
JUN-2017	11787	3537

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
June 2017

N = 7239

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2017

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2017

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2017

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2017

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2017

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>34</b>	<b>47</b>	<b>24</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>71</b>	<b>93</b>	<b>49</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>346</b>	<b>459</b>	<b>270</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	17
	35-49	*	*	36
	50+	*	*	79
<b>Total HSDA:</b>	<b>173</b>	<b>231</b>	<b>132</b>	
<b>Total HA:</b>		<b>624</b>	<b>830</b>	<b>475</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	65	66	*
	35-49	170	194	*
	50+	384	565	*
<b>Total HA:</b>		<b>624</b>	<b>830</b>	<b>475</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	489	660	379
Female	135	170	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	475	53	580	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	5	*
	<5 years	11	*
	<b>Total HSDA:</b>	<b>34</b>	<b>24</b>
KOOTENAY BOUNDARY	10 years or more	39	26
	5 years or more	19	14
	<5 years	13	9
	<b>Total HSDA:</b>	<b>71</b>	<b>49</b>
OKANAGAN	10 years or more	187	137
	5 years or more	83	66
	<5 years	76	67
	<b>Total HSDA:</b>	<b>346</b>	<b>270</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	91	61
	5 years or more	37	33
	<5 years	45	38
	<b>Total HSDA:</b>	<b>173</b>	<b>132</b>
<b>Total HA:</b>		<b>624</b>	<b>475</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	335	235
	5 years or more	144	117
	<5 years	145	123
<b>Total HA:</b>		<b>624</b>	<b>475</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	37	53	14	23
KOOTENAY BOUNDARY	63	112	23	36
OKANAGAN	200	712	63	270
THOMPSON/CARIBOO/SHUSWAP	127	450	35	120
<b>Total:</b>	<b>427</b>	<b>1327</b>	<b>135</b>	<b>449</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>94</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	26	27	18
	35-49	107	118	76
	50+	194	261	150
	<b>Total HSDA:</b>	<b>333</b>	<b>412</b>	<b>249</b>
FRASER NORTH	0-19	13	13	*
	20-34	114	115	*
	35-49	350	389	*
	50+	500	788	*
	<b>Total HSDA:</b>	<b>977</b>	<b>1305</b>	<b>758</b>
FRASER SOUTH	0-19	11	11	8
	20-34	92	94	69
	35-49	375	428	312
	50+	457	675	378
	<b>Total HSDA:</b>	<b>935</b>	<b>1208</b>	<b>767</b>
<b>Total HA:</b>		<b>2245</b>	<b>2925</b>	<b>1774</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	30	30	16
	20-34	232	236	172
	35-49	832	935	658
	50+	1151	1724	928
<b>Total HA:</b>		<b>2245</b>	<b>2925</b>	<b>1774</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1708	2255	1376
Female	537	670	398

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1774	50	610	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	169	116
	5 years or more	99	84
	<5 years	65	49
	<b>Total HSDA:</b>	<b>333</b>	<b>249</b>
FRASER NORTH	10 years or more	483	347
	5 years or more	239	194
	<5 years	255	217
	<b>Total HSDA:</b>	<b>977</b>	<b>758</b>
FRASER SOUTH	10 years or more	442	351
	5 years or more	250	209
	<5 years	243	207
	<b>Total HSDA:</b>	<b>935</b>	<b>767</b>
<b>Total HA:</b>		<b>2245</b>	<b>1774</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1094	814
	5 years or more	588	487
	<5 years	563	473
<b>Total HA:</b>		<b>2245</b>	<b>1774</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	130	435	40	91
FRASER NORTH	238	1480	59	258
FRASER SOUTH	205	1226	46	348
<b>Total:</b>	<b>573</b>	<b>3141</b>	<b>145</b>	<b>697</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	180
FRASER NORTH	639
FRASER SOUTH	515
<b>Total:</b>	<b>1334</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	27
	35-49	*	*	65
	50+	*	*	188
	<b>Total HSDA:</b>		<b>327</b>	<b>468</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>160</b>	<b>206</b>
VANCOUVER	0-19	47	50	5
	20-34	446	457	353
	35-49	1493	1708	1102
	50+	2581	4328	1999
	<b>Total HSDA:</b>	<b>4567</b>	<b>6543</b>	<b>3459</b>
<b>Total HA:</b>		<b>5054</b>	<b>7217</b>	<b>3866</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	51	54	6
	20-34	499	511	398
	35-49	1621	1853	1202
	50+	2883	4799	2260
<b>Total HA:</b>		<b>5054</b>	<b>7217</b>	<b>3866</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4447	6343	3416
Female	605	872	450

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3866	52	610	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	170	138
	5 years or more	72	65
	<5 years	85	77
	<b>Total HSDA:</b>	<b>327</b>	<b>280</b>
RICHMOND	10 years or more	77	55
	5 years or more	41	33
	<5 years	42	39
	<b>Total HSDA:</b>	<b>160</b>	<b>127</b>
VANCOUVER	10 years or more	2411	1730
	5 years or more	1215	939
	<5 years	941	790
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4567</b>	<b>3459</b>
<b>Total HA:</b>	<b>5054</b>	<b>3866</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2658	1923
5 years or more	1328	1037
<5 years	1068	906
Never on ART	0	0
<b>Total HA:</b>	<b>5054</b>	<b>3866</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	151	390	57	105
RICHMOND	42	272	15	97
VANCOUVER	557	10245	213	5326
<b>Total:</b>	<b>750</b>	<b>10907</b>	<b>285</b>	<b>5528</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>107</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>297</b>	<b>416</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>114</b>	<b>151</b>
SOUTH VANCOUVER ISLAND	0-19	5	5	*
	20-34	57	59	*
	35-49	199	234	*
	50+	430	662	*
	<b>Total HSDA:</b>		<b>691</b>	<b>960</b>
<b>Total HA:</b>		<b>1102</b>	<b>1527</b>	<b>880</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	6
	20-34	96	101	71
	35-49	319	367	259
	50+	677	1049	544
<b>Total HA:</b>		<b>1102</b>	<b>1527</b>	<b>880</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	896	1243	717
Female	206	284	163

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	880	53	495	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	141	117
	5 years or more	72	60
	<5 years	84	71
	<b>Total HSDA:</b>	<b>297</b>	<b>248</b>
NORTH VANCOUVER ISLAND	10 years or more	57	47
	5 years or more	29	23
	<5 years	28	22
	<b>Total HSDA:</b>	<b>114</b>	<b>92</b>
SOUTH VANCOUVER ISLAND	10 years or more	362	260
	5 years or more	168	137
	<5 years	161	143
	<b>Total HSDA:</b>	<b>691</b>	<b>540</b>
<b>Total HA:</b>		<b>1102</b>	<b>880</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	560	424
	5 years or more	269	220
	<5 years	273	236
<b>Total HA:</b>		<b>1102</b>	<b>880</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	177	795	78	211
NORTH VANCOUVER ISLAND	125	249	43	76
SOUTH VANCOUVER ISLAND	192	1619	40	547
<b>Total:</b>	<b>494</b>	<b>2663</b>	<b>161</b>	<b>834</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	41
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	97
<b>Total:</b>	<b>168</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>40</b>	<b>48</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	19
	50+	*	*	24
	<b>Total HSDA:</b>		<b>68</b>	<b>103</b>
NORTHERN INTERIOR	0-19	7	7	*
	20-34	22	25	*
	35-49	74	90	*
	50+	82	133	*
	<b>Total HSDA:</b>		<b>185</b>	<b>255</b>
<b>Total HA:</b>		<b>293</b>	<b>406</b>	<b>210</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	33	40	*
	35-49	113	144	*
	50+	138	213	*
<b>Total HA:</b>		<b>293</b>	<b>406</b>	<b>210</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	180	253	132
Female	113	153	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	210	49	550	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	16	7
	5 years or more	15	10
	<5 years	9	6
	<b>Total HSDA:</b>	<b>40</b>	<b>23</b>
NORTH WEST	10 years or more	21	10
	5 years or more	32	26
	<5 years	15	13
	<b>Total HSDA:</b>	<b>68</b>	<b>49</b>
NORTHERN INTERIOR	10 years or more	63	39
	5 years or more	61	52
	<5 years	61	47
	<b>Total HSDA:</b>	<b>185</b>	<b>138</b>
<b>Total HA:</b>		<b>293</b>	<b>210</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	100	56
5 years or more	108	88
<5 years	85	66
<b>Total HA:</b>	<b>293</b>	<b>210</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	7	11
NORTH WEST	66	149	19	28
NORTHERN INTERIOR	102	414	16	182
<b>Total:</b>	<b>201</b>	<b>622</b>	<b>42</b>	<b>221</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	12
NORTHERN INTERIOR	22
<b>Total:</b>	<b>40</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	32	*
	THOMPSON/CARIBOO/SHUSWAP	*	39	*
	<b>Total HA:</b>	<b>49</b>	<b>88</b>	<b>37</b>
FRASER	FRASER EAST	32	41	26
	FRASER NORTH	52	84	40
	FRASER SOUTH	80	109	62
	<b>Total HA:</b>	<b>164</b>	<b>234</b>	<b>128</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	47	23
	RICHMOND	9	14	8
	VANCOUVER	500	811	419
	<b>Total HA:</b>	<b>535</b>	<b>872</b>	<b>450</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	77	45
	NORTH VANCOUVER ISLAND	14	23	13
	SOUTH VANCOUVER ISLAND	34	73	30
	<b>Total HA:</b>	<b>99</b>	<b>173</b>	<b>88</b>
NORTHERN	NORTH EAST	8	10	5
	NORTH WEST	32	58	25
	NORTHERN INTERIOR	67	100	58
	<b>Total HA:</b>	<b>107</b>	<b>168</b>	<b>88</b>
<b>Total:</b>		<b>954</b>	<b>1535</b>	<b>791</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	593	980	488
Female	361	555	303

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	791	50	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicstat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

